|
Activity Number:
|
73
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Sunday, August 6, 2006 : 4:00 PM to 5:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #307072 |
|
Title:
|
Optimal Trial Designs for Screening Cancer Therapeutic Agents
|
|
Author(s):
|
Vandana Mukhi*+ and Yongzhao Shao and Judith D. Goldberg
|
|
Companies:
|
New York University School of Medicine and New York University and New York University School of Medicine
|
|
Address:
|
60 Sunflower Ridge Road, South Setauket, NY, 11720,
|
|
Keywords:
|
phase II ; false discovery rate ; clinical trial ; design
|
|
Abstract:
|
With the large number of new cancer therapeutic agents under development, investigators are seeking to design and implement clinical trials to improve outcomes for cancer patients. Improved methods for the prioritization and selection of new treatments for phase III evaluation can expedite the delivery of new agents to patients. We can accomplish this goal for improvements in study designs and procedures to screen out inefficacious treatments and select those treatments that are truly effective in a cost-effective manner. We focus on the evaluation and comparison of several optimal phase II screening trial designs based on the False Discovery Rate (FDR) and other criteria. Simulation results will be discussed.
|
